ストックスクリーナーアプリを入手
106.92
5.08%
-5.72
前日終値:
$112.64
開ける：
$113.06
24時間の取引高:
1.05M
Relative Volume:
1.11
時価総額：
$5.84B
収益：
$1.34M
当期純損益:
$-173.66M
株価収益率:
-25.84
EPS:
-4.1385
ネットキャッシュフロー:
$-130.49M
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
+9.68%
6か月 パフォーマンス:
+100.26%
1年 パフォーマンス:
+417.27%
1日の値動き範囲:
$105.66
$114.55
1週間の範囲:
$100.00
$114.55
52週間の値動き範囲:
$18.08
$114.55
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Compare DNTH vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
106.92 | 5.71B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | Wolfe Research | Outperform |
| 2026-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | 開始されました | Truist | Buy |
| 2025-07-02 | 開始されました | William Blair | Outperform |
| 2024-12-20 | 開始されました | TD Cowen | Buy |
| 2024-10-03 | 開始されました | Oppenheimer | Outperform |
| 2024-07-26 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-15 | 開始されました | Stifel | Buy |
| 2023-12-26 | 開始されました | Jefferies | Buy |
| 2023-11-22 | 開始されました | Wedbush | Outperform |
| 2023-10-30 | 開始されました | Guggenheim | Buy |
| 2023-09-28 | 開始されました | Raymond James | Outperform |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-06 | アップグレード | Goldman | Neutral → Buy |
| 2021-08-20 | 再開されました | Goldman | Neutral |
| 2021-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-22 | 繰り返されました | B. Riley Securities | Buy |
| 2021-06-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-18 | 開始されました | B. Riley Securities | Buy |
| 2021-01-07 | 開始されました | Mizuho | Buy |
| 2020-06-08 | アップグレード | Goldman | Neutral → Buy |
| 2019-03-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
すべてを表示
Dianthus Therapeutics Inc (DNTH) 最新ニュース
Dianthus Therapeutics, Inc. $DNTH Shares Bought by SummitTX Capital L.P. - MarketBeat
Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dianthus Therapeutics Inc (DNTH) Cash Flow - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics, Inc. Revenue Breakdown – NASDAQ:DNTH - TradingView
Dianthus Therapeutics, Inc. Revenue Breakdown – BOATS:DNTH - TradingView
Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNTH|Dianthus Therapeutics Inc|Price:103.870|Chg%:-0.920 - TradingKey
Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Jennison Associates LLC Buys New Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineProfit Announcement - dars.gov.et
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
Dianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trial - TIKR.com
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – FWB:87E - TradingView
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
Dianthus Therapeutics DNTH Jumps As Phase 3 EMERGE Trial Kicks Off - timothysykes.com
DNTH Stock Pops As Phase 3 EMERGE Trial Kicks Off - StocksToTrade
Dianthus Therapeutics stock hits 52-week high at 102.38 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 102.38 USD - Investing.com India
Dianthus Therapeutics Rockets As Phase 3 Hype Builds - TipRanks
Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares By Investing.com - Investing.com Australia
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares - Investing.com
Dianthus Therapeutics (DNTH) CFO sells 31,249 shares in 10b5-1 trades - Stock Titan
Dianthus Therapeutics (DNTH) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentMid-Term Outlook - Bölüm Sonu Canavarı
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - Sahm
Form 144 Dianthus Therapeutics For: 9 July By Investing.com - Investing.com South Africa
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 99.36 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 99.36 USD - Investing.com
Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market - TipRanks
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTHDianthus Therapeutics Inc Revenue Breakdown - Finviz
Dianthus Therapeutics Inc. Q1 2026 Earnings: EPS Surprise of 22.28% Drives Positive Stock ReactionRevenue Per Share - dars.gov.et
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cartesian Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - Sahm
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com - Investing.com South Africa
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
Dianthus Therapeutics Inc (DNTH) 財務データ
収益
当期純利益
現金流量
EPS
Dianthus Therapeutics Inc (DNTH) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | EVP, CFO & CBO |
Jul 09 '26 |
Sale |
101.03 |
31,249 |
3,157,151 |
0 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):